Eigil Kjeldsen1, Christopher Veigaard. 1. Hemodiagnostic Laboratory, Cancer Cytogenetics Section, Department of Hematology, Aarhus University Hospital, Tage-Hansens Gade 2, Ent. 4A, 8000, Aarhus C, Denmark, Eigil.Kjeldsen@ki.au.dk.
Abstract
BACKGROUND: Acute myeloid leukemia with a normal karyotype (NK-AML) has been assigned to an intermediate prognostic risk group. However, there is a marked variability in outcome within this group of AML, suggesting a significant biological and molecular heterogeneity. Chromosomal abnormalities may be cryptic by metaphase cytogenetics, but still have an impact on the process of leukemogenesis and/or the clinical outcome of NK-AML. Therefore, we analyzed the genomic complement of NK-AML cases to search for the presence of submicroscopic genomic imbalances. METHODS: We applied high-resolution oligo-based aCGH analysis to a cohort of AML patients with a normal karyotype, and FISH to validate the aCGH findings. Relative gene expression levels were examined by qPCR. RESULTS: High-resolution aCGH analysis of 21 NK-AML patients revealed one patient with a rare submicroscopic deletion at 7q31.1. This female patient exhibited a rapid disease progression and a dismal outcome. The deletion was mono-allelic, approximately 189,1 kb in size, and encompassed the major 3' part of the DOCK4 gene. The expression level of the DOCK4 gene in her leukemic cells was decreased when compared to CD34+ cells from healthy controls. When compared to AML patients with -7/del(7q) as the sole chromosomal anomaly, the DOCK4 expression level was found to be similarly low. CONCLUSIONS: This is the first report of an acquired partial deletion of the DOCK4 gene in a patient with de novo NK-AML. DOCK4 is a strong tumor suppressor candidate, required for GTPase activation in signal transduction pathways controlling cellular proliferation, adhesion, migration and phagocytosis. Our findings may be relevant for understanding of the process of leukemogenesis and the response to therapy in a subset of NK-AML patients.
BACKGROUND: Acute myeloid leukemia with a normal karyotype (NK-AML) has been assigned to an intermediate prognostic risk group. However, there is a marked variability in outcome within this group of AML, suggesting a significant biological and molecular heterogeneity. Chromosomal abnormalities may be cryptic by metaphase cytogenetics, but still have an impact on the process of leukemogenesis and/or the clinical outcome of NK-AML. Therefore, we analyzed the genomic complement of NK-AML cases to search for the presence of submicroscopic genomic imbalances. METHODS: We applied high-resolution oligo-based aCGH analysis to a cohort of AMLpatients with a normal karyotype, and FISH to validate the aCGH findings. Relative gene expression levels were examined by qPCR. RESULTS: High-resolution aCGH analysis of 21 NK-AMLpatients revealed one patient with a rare submicroscopic deletion at 7q31.1. This female patient exhibited a rapid disease progression and a dismal outcome. The deletion was mono-allelic, approximately 189,1 kb in size, and encompassed the major 3' part of the DOCK4 gene. The expression level of the DOCK4 gene in her leukemic cells was decreased when compared to CD34+ cells from healthy controls. When compared to AMLpatients with -7/del(7q) as the sole chromosomal anomaly, the DOCK4 expression level was found to be similarly low. CONCLUSIONS: This is the first report of an acquired partial deletion of the DOCK4 gene in a patient with de novo NK-AML. DOCK4 is a strong tumor suppressor candidate, required for GTPase activation in signal transduction pathways controlling cellular proliferation, adhesion, migration and phagocytosis. Our findings may be relevant for understanding of the process of leukemogenesis and the response to therapy in a subset of NK-AMLpatients.
Authors: K Fischer; S Fröhling; S W Scherer; J McAllister Brown; C Scholl; S Stilgenbauer; L C Tsui; P Lichter; H Döhner Journal: Blood Date: 1997-03-15 Impact factor: 22.113
Authors: Megan E McNerney; Christopher D Brown; Xiaoyue Wang; Elizabeth T Bartom; Subhradip Karmakar; Chaitanya Bandlamudi; Shan Yu; Jinkyung Ko; Barry P Sandall; Thomas Stricker; John Anastasi; Robert L Grossman; John M Cunningham; Michelle M Le Beau; Kevin P White Journal: Blood Date: 2012-12-03 Impact factor: 22.113
Authors: Sriram Sundaravel; Wen-Liang Kuo; Jong Jin Jeong; Gaurav S Choudhary; Shanisha Gordon-Mitchell; Hui Liu; Tushar D Bhagat; Kathy L McGraw; Sandeep Gurbuxani; Alan F List; Amit Verma; Amittha Wickrema Journal: Clin Cancer Res Date: 2019-07-15 Impact factor: 12.531
Authors: Sriram Sundaravel; Ryan Duggan; Tushar Bhagat; David L Ebenezer; Hui Liu; Yiting Yu; Matthias Bartenstein; Madhu Unnikrishnan; Subhradip Karmakar; Ting-Chun Liu; Ingrid Torregroza; Thomas Quenon; John Anastasi; Kathy L McGraw; Andrea Pellagatti; Jacqueline Boultwood; Vijay Yajnik; Andrew Artz; Michelle M Le Beau; Ulrich Steidl; Alan F List; Todd Evans; Amit Verma; Amittha Wickrema Journal: Proc Natl Acad Sci U S A Date: 2015-11-02 Impact factor: 11.205